返回 
加入收藏
非鳞癌型非小细胞肺癌患者首次化疗后无进展生存期的影响因素分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 非鳞癌型非小细胞肺癌患者首次化疗后无进展生存期的影响因素分析 |
| TITLE： | |
| 摘要： | 目的：探讨非鳞癌型非小细胞肺癌（NSCLC）患者首次化疗后无进展生存期（PFS）的影响因素，为临床个体化治疗方案的制订提供参考。方法：收集2012年1月－2014年12月于我院行首次化疗并接受随访的84例非鳞癌型NSCLC患者的临床资料，回顾性分析患者因素[性别、年龄、功能状态（PS）评分]、疾病因素[肿瘤分期、肿瘤标志物（TM）水平]、治疗因素（化疗方案与疗程、疗效）对其PFS的影响。结果：84例患者的平均随访时间为11.933个月（末次随访时间为2017年6月30日），其中位PFS为4.017个月。其中，男性患者的中位PFS略短于女性患者，≥65岁患者的中位PFS略短于＜65岁患者，PS评分0～1分者的中位PFS略长于2～4分者，差异均无统计学意义（P＞0.05）。Ⅱ～Ⅲ期患者的中位PFS显著长于Ⅳ期患者，至少1项TM指标高于正常值上限10倍者的中位PFS显著短于4项TM指标均低于正常值上限10倍者，完成1～3个疗程者的中位PFS显著短于完成4～6个疗程者，疗效判定为“疾病进展”者的中位PFS显著短于“疾病稳定”及以上者，差异均有统计学意义（P＜0.05）。84例患者中有81例患者选择了PP方案（培美曲塞二钠+铂类），其余选择了非PP方案，由于两者病例数相差较大，故未考察化疗方案对患者PFS的影响。结论：患者的疾病因素和治疗因素可能与其PFS有关，其中肿瘤分期、至少1项TM指标高于正常值上限10倍、完成化疗疗程数、化疗疗效是非鳞癌型NSCLC患者PFS的独立影响因素。 |
| ABSTRACT： | OBJECTIVE： To investigate the factors that influence the progression-free survival time （PFS） of patients with non-squamous cell carcinoma type non-small cell lung cancer （NSCLC） after first chemotherapy， and to provide reference for the formulation of clinical individual treatment regimen. METHODS： Clinical information of 84 patients with non-squamous cell carcinoma type NSCLC after first chemotherapy were selected from our hospital during Jan. 2012-Dec. 2014. The effects of patient’s factors [gender， age， performance status （PS） score]， disease factors [tumor staging， tumor marker （TM） level] and treatment factors （chemotherapy regimen and treatment course， chemotherapy efficacy） on PFS were analyzed retrospectively. RESULTS： All patients were followed up for 11.933 months averagely （final follow-up time of Jun. 30th， 2017）， and their median PFS was 4.017 months. The median PFS of male was slightly shorter than that of female； the median PFS of patients aged more than 65 year-old was slightly shorter than that of patients aged below 65 year-old； the median PFS of patients with PS score of 0-1 was slightly longer than that of patients with PS score of 2-4， without statistical significance （P＞0.05）. The median PFS of Ⅱ-Ⅲ stage patients was significantly longer than that of Ⅳ stage patients； the median PFS of patients with at least one TM index was 10 times higher than the upper limit of the normal value was significantly shorter than that of patients with four TM indexes were all 10 times lower than the upper limit of the normal value； the median PFS of patients underwent 1-3 treatment courses was significantly shorter than that of patients underwent 4-6 treatment courses； the median PFS of patients with progressive disease efficacy was significantly shorter than that of patients with stable disease efficacy or above， with statistical significance （P＜0.05）. Among 84 patients， 81 patients selected PP regimen （pemetrexed disodium+platinum）， and other patients chose non-PP regimen. Due to the large difference in the number of cases， the effect of the chemotherapy regimen on the patient’s PFS was not investigated. CONCLUSIONS： The disease factor and treatment factor of patients may be associated with PFS. Tumor staging， at least one TM index was 10 times higher than the upper limit of the normal value， the number of completed chemotherapy treatment course， chemotherapy efficacy are independent influential factors of PFS in patients with non-squamous cell carcinoma type NSCLC. |
| 期刊： | 2018年第29卷第4期 |
| 作者： | 钱石静，周陶然，吴涓，祝德秋 |
| AUTHORS： | QIAN Shijing，ZHOU Taoran，WU Juan，ZHU Deqiu |
| 关键字： | 非鳞癌型非小细胞肺癌；化疗；无进展生存期；肿瘤分期；肿瘤标志物；化疗疗程；疗效 |
| KEYWORDS： | Non-squamous cell carcinoma type non-small cell lung cancer； Chemotherapy； Progression-free survival time； Tumor staging； Tumor marker； Chemotherapy course； Chemotheray efficacy |
| 阅读数： | 295 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
